Status:
COMPLETED
Study of Infections in Patients With Autoimmune Diseases Treated With Rituximab
Lead Sponsor:
University Hospital, Lille
Collaborating Sponsors:
Grifols Biologicals, LLC
Conditions:
Autoimmune Diseases
Eligibility:
All Genders
18+ years
Brief Summary
Rituximab is a very effective drug used to treat many inflammatory diseases. These diseases include, for example, rheumatoid arthritis, multiple sclerosis and systemic autoimmune diseases. The major ...
Eligibility Criteria
Inclusion
- Patient initiating treatment with RTX, delivered by the central pharmacy of Lille University Hospital
- Inpatient or outpatient at Lille University Hospital (in one of the following departments: internal medicine, rheumatology, neurology, dermatology, pneumology) and monitored every three months as part of routine care (as part of the surveillance of induction of RTX treatment)
- Patient with one of the following autoimmune diseases, defined by international criteria
Exclusion
- Treatment with rituximab for a malignancy or a transplant reject
- Pregnant or lactating women
- People in emergency
- Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system, refusal to sign consent
- Persons deprived of their liberty
- People unable to consent
Key Trial Info
Start Date :
May 29 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT03778840
Start Date
May 29 2019
End Date
May 31 2022
Last Update
February 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Claude Huriez, CHU
Lille, France